Atlas Trials

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Clinical trial NCT03588091 · COMPLETED

Trial details

NCT number
NCT03588091
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
HER2-positive Breast Cancer
Start date
2018-07-24
Primary completion
2024-01-31
Enrollment
355

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.